Orphan Therapeutics, LLC
is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 primarily in the US and Canada where terlipressin is currently not available.
In March 2010, Orphan Therapeutics licensed the New Drug Application (NDA) and its development rights for terlipressin to Ikaria Inc., which was acquired by Mallinckrodt plc in April 2015.
Orphan Therapeutics has a continued commitment to assist the Mallinckrodt team through the FDA approval process.